Wistar Wins Patent for 'Universal' Flu Vaccine Tech; Seeks Corporate Development Partner | GenomeWeb

Philadelphia's Wistar Institute said last week that it has obtained a US patent for a synthetic vaccine technology with the potential to be developed into a universal flu vaccine that could eliminate annual flu shots and protect against pandemics.

Wistar said it is now seeking a corporate partner to license and develop the vaccine, which has been tested in animals and is currently in prototype form.

The newly awarded patent, US No. 7,527,798, is entitled "Composition and method for preventing or treating a virus infection."

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Wall Street Journal reports that National Institutes of Health Director Francis Collins' response to contamination concerns at the agency might have delayed care.

The final revision of the Common Rule doesn't include the proposed change requiring consent for leftover biospecimens.

The first Reproducibility Project: Cancer Biology papers show mixed results.

In Nature this week: mobile phone-based targeted DNA sequencing, and more.